|
Sep 30
|
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
|
|
Sep 30
|
MNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS…
|
|
Jun 20
|
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
|
|
May 14
|
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
|
|
May 7
|
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
|
|
Apr 30
|
MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years ago
|
|
Apr 2
|
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
|
|
Mar 26
|
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
|
|
Mar 20
|
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
|
|
Mar 20
|
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
|
|
Mar 12
|
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
|
|
Feb 29
|
MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…
|
|
Dec 21
|
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
|
|
Dec 6
|
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
|
|
Nov 27
|
MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…
|
|
Apr 30
|
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
|